辉瑞(PFE.US)超长效减重疗法取得积极顶线结果将启动3期试验

智通财经02-04

智通财经APP获悉，2月3日，辉瑞(PFE.US)宣布，其超长效注射用GLP-1受体激动剂(RA)PF'3944(MET-097i)在2b期VESPER-3研究中取得积极顶线结果。该研究针对肥胖或超重、不合并2型糖尿病的成人患者，评估每月一次维持给药方案。PF'3944是一款超长效、完全偏向性的GLP-1受体激动剂，是辉瑞通过近期收购Metsera所获得的管线，具有每月注射1次的给药潜力。目前正被...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2608952381?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-04 07:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608952381","market":"us","top_or_hot":-1,"title":"辉瑞(PFE.US)超长效减重疗法取得积极顶线结果 将启动3期试验","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，2月3日，辉瑞(PFE.US)宣布，其超长效注射用GLP-1受体激动剂(RA)PF'3944(MET-097i)在2b期VESPER-3研究中取得积极顶线结果。该研究针对肥胖或超重、不合并2型糖尿病的成人患者，评估每月一次维持给药方案。PF'3944是一款超长效、完全偏向性的GLP-1受体激动剂，是辉瑞通过近期收购Metsera所获得的管线，具有每月注射1次的给药潜力。目前正被...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1401319.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>辉瑞(PFE.US)超长效减重疗法取得积极顶线结果 将启动3期试验</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n辉瑞(PFE.US)超长效减重疗法取得积极顶线结果 将启动3期试验\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-04 07:53 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1401319.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，2月3日，辉瑞(PFE.US)宣布，其超长效注射用GLP-1受体激动剂(RA)PF'3944(MET-097i)在2b期VESPER-3研究中取得积极顶线结果。该研究针对肥胖或超重、不合并2型糖尿病的成人患者，评估每月一次维持给药方案。PF'3944是一款超长效、完全偏向性的GLP-1受体激动剂，是辉瑞通过近期收购Metsera所获得的管线，具有每月注射1次的给药潜力。目前正被...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1401319.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B19Z3581.USD","symbol_name":"Legg Mason ClearBridge - Value A Acc USD","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1401319.html","article_id":"2608952381","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608952381","pubTimestamp":1770162821,"columns":[{"name":"产品发布","id":31,"label_key":"productRelease"}],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，2月3日，辉瑞宣布，其超长效注射用GLP-1受体激动剂PF'3944在2b期VESPER-3研究中取得积极顶线结果。该研究针对肥胖或超重、不合并2型糖尿病的成人患者，评估每月一次维持给药方案。结果显示，治疗第28周，第1组和第3组患者的体重分别较安慰剂组降低了10%和12.3%。安慰剂组中没有因AEs而中止治疗的情况。辉瑞计划推进大规模肥胖开发项目，预计在2026年启动20项以上临床试验。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4592":"伊斯兰概念","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","PFE":"辉瑞","BK4588":"碎股","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","BK4581":"高盛持仓","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0122379950.USD":"贝莱德世界健康科学A2","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","BK4007":"制药","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0058720904.USD":"联博国际健康护理基金A","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","SG9999001176.USD":"United Global Healthcare Acc USD","BK4599":"减肥药","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","BK4585":"ETF&股票定投概念","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","BK4534":"瑞士信贷持仓","SG9999002232.USD":"Allianz Global High Payout USD","BK4533":"AQR资本管理(全球第二大对冲基金)","SG9999002224.SGD":"Allianz Global High Payout SGD"},"translate_title":"Pfizer (PFE.US) ultra-long-acting weight loss therapy achieves positive top-line results and will start phase 3 trials","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":1.98},"content_text":"智通财经APP获悉，2月3日，辉瑞(PFE.US)宣布，其超长效注射用GLP-1受体激动剂(RA)PF'3944(MET-097i)在2b期VESPER-3研究中取得积极顶线结果。该研究针对肥胖或超重、不合并2型糖尿病的成人患者，评估每月一次维持给药方案。PF'3944是一款超长效、完全偏向性的GLP-1受体激动剂，是辉瑞通过近期收购Metsera所获得的管线，具有每月注射1次的给药潜力。目前正被开发为每周(QW)单药治疗及每月治疗方案，并探索与多种肽类药物联合应用，包括胰淀素类似物PF-08653945(PF'3945；MET-233i)以及葡萄糖依赖性促胰岛素多肽受体(GIPR)激动剂PF-08654696(MET-034i)。结果显示，治疗第28周，第1组和第3组患者的体重分别较安慰剂组降低了10%和12.3%。这些数据表明，在改为每月1次用药后，患者的体重下降稳健且持续，第28周时仍未见平台期，预计到第64周之前体重仍会持续下降。在第28周期间，PF'3944也保持了良好且有利的安全性特征，与GLP-1RA类药物的特征一致。观察到的胃肠道治疗期间不良事件(TEAEs)以轻度或中度为主，所有剂量组中仅有1例严重恶心或呕吐，无严重腹泻。在第1和第3组中，每周阶段有5例患者因不良事件(AEs)停止治疗，5例患者在月度阶段因AEs停止治疗。安慰剂组中没有因AEs而中止治疗的情况。在近期收购Metsera并与YaoPharma达成全球独家合作与许可协议后，辉瑞目前已建立多样化的临床阶段肥胖候选药物管线，涵盖靶向GLP-1受体的注射剂与口服药物，以及GIPR激动剂与拮抗剂，以及胰淀素类似物。辉瑞计划推进大规模肥胖开发项目，预计在2026年启动20项以上临床试验。其中包括PF'3944的10项3期研究：已启动的3期关键性VESPER-4研究，评估每周一次PF'3944用于无2型糖尿病的肥胖或超重人群；计划开展的3期VESPER-5研究，评估每周一次PF'3944用于合并2型糖尿病的肥胖或超重人群；计划开展的3期VESPER-6研究，评估每月一次PF'3944用于肥胖或超重人群；以及至少7项其他计划中的3期研究，旨在覆盖合并症并提高患者治疗选择与可及性。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2608952381","isCrawlerRequest":true}

辉瑞(PFE.US)超长效减重疗法取得积极顶线结果 将启动3期试验

精彩评论

辉瑞(PFE.US)超长效减重疗法取得积极顶线结果将启动3期试验